An exploratory pharmacokinetic/pharmacodynamic study of CERC 301 in inpatients with major depressive disorder.
Phase of Trial: Phase I
Latest Information Update: 25 Mar 2015
At a glance
- Drugs Rislenemdaz (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Cerecor
- 25 Mar 2015 New trial record
- 20 Mar 2015 Results published in the Media Release.